Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Hefti, Marco M ^a   Hu, Rong ^b   Knoblauch, Nicholas W ^a   Collins, Laura C ^a   Haibe Kains, Benjamin ^c   Tamimi, Rulla M ^b   Beck, Andrew H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Biomarkers; Breast cancer; Estrogen receptor; Gene expression microarrays; Immunohistochemistry; Inter assay reproducibility; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; MESSENGER RNA;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PROTEIN EXPRESSION; REPRODUCIBILITY; TISSUE MICROARRAY; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 84882558986     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3462     Document Type: Article

References (32)

1. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
2. Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, Lesperance ML. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol 2004, 22:1769-1770. 10.1200/JCO.2004.99.251, 15118010.
3. Colozza M, Larsimont D, Piccart MJ. Progesterone receptor testing: not the right time to be buried. J Clin Oncol 2005, 23:3867-3868. author reply 3869-3870, 10.1200/JCO.2005.05.167, 15923594.
4. Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol 2005, 23:931-932. author reply 932-933, 10.1200/JCO.2005.05.152, 15681552.
5. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978, 103:1742-1751. 10.1210/endo-103-5-1742, 748014.
6. Horwitz KB, McGuire W. Estrogen control of progesterone receptor in human breast cancer, correlation with nuclear processing of estrogen receptor. J Biol Chem 1978, 253:2223-2228.
7. Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975, 189:726-727. 10.1126/science.168640, 168640.
8. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol 1979, 117:95-110. 10.1007/978-1-4757-6589-2_5, 474293.
9. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6. 10.1186/bcr1639, 1851385, 17239243.
10. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005, 103:2241-2251. 10.1002/cncr.21030, 15844176.
11. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003, 21:1973-1979. 10.1200/JCO.2003.09.099, 12743151.
12. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013, 24:661-668. 10.1093/annonc/mds430, 23022996.
13. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013, 31:203-209. 10.1200/JCO.2012.43.4134, 23233704.
14. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. 3163848, 21802721, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
15. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778. 10.1200/JCO.2007.12.2747, 17876012.
16. Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?. J Clin Pathol 2009, 62:95-96.
17. De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?. J Clin Oncol 2008, 26:335-336. author reply 336-338, 10.1200/JCO.2007.14.8411, 18182677.
18. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005, 123:21-27. 10.1309/4WV79N2GHJ3X1841, 15762276.
19. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004, 96:218-228. 10.1093/jnci/djh025, 14759989.
20. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012, 104:311-325. 10.1093/jnci/djr545, 3283537, 22262870.
21. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412, 3465532, 23000897, Cancer Genome Atlas Network.
22. Carletta J. Assessing agreement on classification tasks: the kappa statistic. Comput Linguist 1996, 22:249-254.
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
24. Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, Schroeder MS, Risch T, Quackenbush J, Haibe-Kains B. Significance analysis of prognostic signatures. PLoS Comput Biol 2013, 9:e1002875. 10.1371/journal.pcbi.1002875, 3554539, 23365551.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
26. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005, 5:388-396. 10.1038/nrc1608, 15864280.
27. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:R67. 10.1186/bcr2128, 2575540, 18681955.
28. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011, 7:e1002240. 10.1371/journal.pcbi.1002240, 3197658, 22028643.
29. Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 2011, 29:1531-1538. 10.1200/JCO.2010.30.3677, 3082973, 21422407.
30. Mackey JR. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?. J Clin Oncol 2011, 29:1504-1506. 10.1200/JCO.2010.34.3202, 21422423.
31. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. J Clin Oncol 2008, 26:1404-1410. 10.1200/JCO.2007.10.6393, 18349391.
32. Sahoo D, Dill DL, Gentles AJ, Tibshirani R, Plevritis SK. Boolean implication networks derived from large scale, whole genome microarray datasets. Genome Biol 2008, 9:R157. 10.1186/gb-2008-9-10-r157, 2760884, 18973690.